Introduction
The cyclooxygenases (COX) are enzymes that catalyze the rate limiting step in the biosynthesis of prostaglandins (PGs), which have also been implicated in various disease states including cancer (1, 2) . Clinical trials have shown that COX inhibitors (NSAIDs) reduce the risk of developing cancer and associated death (3) . In this regard, higher COX2 expression and PG levels have been detected in different tumors, which could explain the NSAIDs beneficial effects in cancer prevention and treatment (3) . Prostaglandin F2 (PGF2) has been scarcely studied on cancer although it has been detected in several tumor types and cancer patient body fluids (4, 5) and only recently has been mechanistically associated with cancer progression (6) . PGF2 is produced through the combined action of cyclooxygenases (COX) and different isomerases, AKR1B1 and AKR1C3 among others, with scarce reports implicating them in cancer (7) . PGF2 binds and signals through the prostaglandin F receptor (PTGFR), a G protein coupled receptor, coupling mainly to Gq, thus leading to an increase in intracellular Ca 2+ levels (8) . Consequently, PGF2 binding to FP will cause Ca 2+ /calcineurin activation of the NFAT transcription factors, implicated in a growing variety of physiological and pathological functions, including cancer (9) .
On the other hand, previous studies have shown there are cell and stage specific increases of COX, prostaglandin synthases and receptors in epithelial ovarian cancer (EOC), supporting the hypothesis that PG synthesis and signaling are of importance for malignant transformation and progression in EOC (10, 11) . EOC, which comprises 90% of all ovarian malignancies, is the leading cause of death from gynecological cancer, in developed countries (12) . Moreover, the majority of patients are diagnosed in advanced cancer stages and the average 5-year survival rate is low (13) . Increased contents of prostaglandins in ovarian tumors have been described in previous studies, possibly regulating cell proliferation and apoptosis in this specific tumor context (11) , being PGE2 the most extensively studied in this context (10) . However, we have found another PG with an emerging role in colon cancer progression (6) with a close relationship with the female reproductive system (14) . PMEPA1 (also known as TMEPA1, transmembrane prostate androgen induced 1) gene was first identified as a highly androgen-inducible gene with abundant expression in prostatic epithelial cells, which eventually was described as a direct transcriptional target of the androgen receptor (AR) (15) but also being upregulated in renal cell carcinoma (16) . PMEPA1 expression, has been found in primary and metastatic pancreatic, endometrial, ovarian, colorectal, breast, lung and prostate tumors (17) (18) (19) (20) although its role has been scarcely explored.
PMEPA1 is known to be induced by transforming growth factor-β (TGF-β) (18) . The TGF- cytokine and the related signaling pathway are key players in mammalian health and disease, with an extensively studied, yet controversial role in cancer (21) . Moreover, TGF- has been shown to control ovarian cancer cell proliferation (22) . PMEPA1 downregulates TGF-β signaling by competing with SARA (SMAD anchor for receptor activation) for R-SMAD binding to sequester R-SMAD phosphorylation and promoting lysosomal degradation of TGF-β receptor (23) . PMEPA1, through a negative feedback loop, is described as the responsible to switch TGFβ from a tumor suppressor to a tumor promoter in breast cancer (20) . In addition, TGF-β-dependent growth of aggressive breast cancer has been suggested to depend on increased expression of PMEPA1 gene (19) . PMEPA1 has been also described as a Wnt/β-catenin cascade target gene (24, 25) , which aberrant activation could contribute to neoplasia. In the case of endometrioid ovarian carcinomas, this stabilization is due to mutations identified in the CTNNB1 gene (26) , while for the rest, this pathway remains unaltered (27) . β-catenin also binds with the intracellular domain of epithelial-cadherin (E-Cadherin) to form a complex which subsequently connects to the actin cytoskeleton, mediates intercellular adhesion, and regulates tumor cell invasion and metastasis (28) . 6 Several oncogenic pathways (i.e., Wnt/β-catenin) increase cell plasticity (29) . TGF-β is a potent regulator of cell plasticity through the induction of epithelial to mesenchymal transition (EMT) (30) , directly activating the expression of transcription factors such as SNAI1/2, Twist and ZEB1/2, which are the key regulators of the EMT program. Related to this, SMADs (SMAD2 and SMAD3 particularly) have been proposed as critical mediators in EMT (31, 32) . In view of this information, and since PMEPA1 is described as SMAD2/3 interacting protein, affecting TGF-β target genes transcription, the possible implication of PMEPA1 in EMT and cell plasticity regulation is worth to be studied.
Here, we have identified, for the first time, PMEPA1 as a COX2/PGF2 up-regulated gene through the induction of TGF and we have deciphered its role in ovarian cancer progression.
We have found that PGF2 induced TGFB1 and PMEPA1 and we provide new evidence of its important role in ovarian cancer progression. Moreover, our results indicate that PMEPA1 is a critical regulator of epithelial plasticity, conferring a growth advantage in ovarian cancer cells.
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RESULTS
Induction of TGFB1 expression by PGF2α
TGF is a crucial factor for ovarian homeostasis as well as for tumorigenesis (22) . Indeed, our gene expression analysis of the TCGA TARGET GTEx patient cohort RNA sequencing data using the UCSC XENA cancer browser shows a 2-fold increase of TGFB1 mRNA levels in ovarian tumor samples, as compared to normal ovarian tissue ( fig. 1A ). PGF2 α has an important role in the female reproductive system and is known to be produced in the ovary, as is produced also in ovarian tumors (11) . Interestingly, we found that PGF2 α significantly increased TGFB1 mRNA levels in ovarian serous adenocarcinoma SKOV3 cells ( fig. 1B ). PGF2 signals through the PTGFR, activating calcium-calcineurin (Ca 2+ /CaN) -nuclear factor of activated T cells (NFAT) (33) . Indeed, Ca 2+ ionophore A23287 significantly increased TGFB1 mRNA levels in SKOV3 cells. TGFB1 mRNA levels correlated to the PTGS2 mRNA levels (Pearson´s r = 0.20, p < 0.0001, n = 369), as they did with the PTGFR mRNA levels as well ( fig. 1C ). Since we already found TGFB1 was induced in response to Ca 2+ signaling, we checked the mRNA levels of the NFAT-coding genes, to find that NFATC2 is more than 2 fold up-regulated in ovarian tumor samples as compared to healthy tissue (p < 0.0001, n = 514) ( fig. 1D ). Moreover, NFATC2 and TGFB1 mRNA levels correlated strongly in the same patient cohort ( fig. 1E ), as did also NFATC1 and TGFB1 (Pearson´s rho = 0.41, p < 0.0001, n = 369). As expected, TGFB1 levels also correlated with the RCAN1 levels (a bona-fide NFAT transcriptional target) mRNA levels in SKOV3 cells ( fig. 1F ).
Along these lines, multiple NFATc1 binding sites were identified in the promoter region of TGFB1, using chromatin immunoprecipitation and mass sequencing (ChIP-seq) data of the Gene Transcription Regulation Database (GTRD), two of them in TGFB1 gene regulatory region located in its first intron (suppl. Fig. 1 ), Site IDs: 34541886-7. They were adjacent to c-fos binding sites, which could serve for co-activation, indicating a possible regulation of TGFB1 by PGF2/NFAT, in 8 agreement with the TGFB1 induction by PGF2 or A23187 and expression correlation with RCAN1. Moreover, 3 EGR1-binding sites were found in the same regulatory region, site IDs 17860197-9. Remarkably, EGR1 is a transcription factor we found previously to be induced by PGF2 (6) . In accordance to this, we also observed that TGFB1 and EGR1 mRNA levels are correlated (r = 0.29, p < 0.0001, n = 369).
All these findings could indicate a close relationship between the COX-2/PGF2/FP/Ca 2+ /NFAT pathway and TGFB1.
PMEPA1 levels are elevated in patients' ovarian tumor samples
PMEPA1 has been proposed as a TGF-induced gene able to convert TGF from a tumor suppressor to a tumor promoter (20) . Indeed, we found that there is a strong correlation (Pearson´s r = 0.34) between TGFB1 and PMEPA1 mRNA levels in the TCGA ovarian cancer cohort Additionally, we found tumor PMEPA1 mRNA levels to be significantly higher than in normal ovary ( fig. 1I ).
To confirm these findings at the protein level, we performed immunohistochemistry analyses on normal tissue obtained from ovary fallopian tubes, fimbriae and peritoneal as well as in ovarian primary tumors and relapses. Primary ovarian tumors showed strong PMEPA1 staining in all of the tumor cells compared to normal tissues that showed diffuse expression in some epithelial cells (Fig. 2) .
We decided to further explore the effect of PMEPA1 expression on patient survival.
Since the patient cohort we used for PMEPA1 protein levels includes only high-grade tumors and most of them resulted positive for PMEPA1, no significant differences in patient survival according to PMEPA1 expression could be obtained. However, after analysis of the gene expression databases available (TCGA ovarian cancer), high PMEPA1 expression is associated with lower survival probability (suppl. Fig. 2 ). The above observations suggest PMEPA1 could have an important role in ovarian cancer progression and it could be considered as a potential biomarker for ovarian tumor characterization and patient stratification.
Induction of PMEPA1 expression by PGF2α
To study the PMEPA1 induction by TGF or PGF2, we selected several ovarian cancer cell lines with different basal PMEPA1 mRNA levels, from higher to lower, namely, SKOV3, OVCAR8, TOV112D and A2780 ( fig. 3A ), as quantified in the Cancer Cell Line Encyclopedia (34) .
Treatment with fluprostenol, a metabolically stable PGF2α analog, was able to increase PMEPA1 mRNA levels, as did TGF treatment, in all the 4 cell lines tested. The combination of both treatments had a partially additive effect ( Fig. 3B ). We generated Skov3 derived cell lines transduced with lentiviral vectors able to express shRNAs that could knockdown PTGFR mRNA, thus decreasing PTGFR levels and signaling. When the resulting cell lines were treated with PGF2 To further investigate the role of Ca 2+ /NFAT and its possible cooperation with TGF signaling, we analyzed PMEPA1 promoter activity. Two luciferase reporter constructs of the PMEPA1 gene were used: the PMEPA1 promoter fragment -1972PMEPA1-luc and PMEPA1 first intron pGL3ti-850 (24) . The activity of pGL3ti-850 has been demonstrated to be potentiated by TGF-β as well as by the -catenin/TCF4 complex (24, 25) . In SKOV3 cells, pGL3ti-850 was also stimulated by TGFβ treatment but not by fluprostenol alone, although it showed a strong synergistic activity with TGFβ. On the other hand, -1972PMEPA1-luc was only activated by the combination of fluprostenol and TGFβ (Fig. 3F ). These results would indicate that SMADs and NFAT co-operatively stimulate PMEPA1 mRNA expression, while the PGF2 induction of PMEPA1 could be partially due to TGFB1 induction.
We searched the GTRD ChIP-seq data and identified multiple NFATc1 binding sites, Site IDs 24982307-11, in the promoter and in the first intron regulatory regions of PMEPA1.
Interestingly, we found several SMAD-2, SMAD-3 binding sites adjacent to the NFATc1 ones, as well as c-Jun and c-Fos (AP1, a common partner of NFAT) binding sites, which could offer coactivator binding to enhance transcriptional activation (suppl. figure 3 ).
All the above suggests that there could be a co-operation of NFAT with SMADs for basal levels maintenance as well as super-induction of PMEPA1. These results suggest that there is a positive feedback loop between PGF2α/NFAT and TGFβ for PMEPA1 expression. TGF induced PMEPA1 expression can be further potentiated by the PGF2/Ca 2+ /CaN pathway, both through its main promoter as by the first intron enhancer.
PMEPA1 overexpression in cancer cells enhances cell growth
To investigate the biological effects of PMEPA1 in tumor cells, we generated ovarian cancer cell lines (Skov3, OVCAR8, A2780, TOV112D and TOV21G), stably overexpressing PMEPA1 and compared them with control cells carrying the empty vector (EV). Additionally, 5 knockdown SKOV3-Luc cell lines for PMEPA1 were generated. Knockdown or overexpression were confirmed by RT-qPCR, WB and immunocytochemistry of thin layer preparations (suppl. figure   4 ).
Interestingly, PMEPA1 overexpressing SKOV3 cells had a higher proliferative rate than 
PMEPA1 overexpression favors a partially epithelial phenotype
Next, we addressed the cellular and molecular characteristics that may contribute to these important differences in ovarian tumor cells. SKOV3 cells have been classified as "intermediate mesenchymal phenotype cells", through phenotypic and genomic attributes (35) , in agreement with the fibroblast-like morphology the cells have in culture. On the other hand, OVCAR8 cells are classified as epithelial, while TOV112D and A2789 are classified as mesenchymal. Once SKOV3 cells were transduced with the PMEPA1 expression vector, morphological changes began to be noticeable towards a more epithelial phenotype (Fig. 5A ).
We observed similar changes in other ovarian cells lines like A2780, TOV21G and TOV112D upon transfection with the PMEPA1 construct while we did not find any changes in transduced Ovcar8 cells. As we detected increased cell-cell contacts, we checked E-cadherin protein expression that was higher in PMEPA1 overexpressing cells ( Fig. 5B ). This is in agreement with our finding that most ovarian tumors tested express both PMEPA1 and E-cadherin ( fig. 2) and supported by the fact that CDH1 is 40-fold more expressed in ovarian tumors as compared to normal ovarian tissue (suppl. fig. 5 ).
Taking into account the phenotypic change and E-cadherin increase, we decided to study β-catenin protein localization in PMEPA1 overexpressing cells, due to the known interaction between the adhesion molecule and the WNT signaling pathway member leading to the retention of the second in the cell membrane proximity (28) 
PMEPA1 overexpression affects the TGF signaling pathway
Increased phosphorylation of SMAD2/3 were observed ( Fig. 6A ) in PMEPA1 overexpressing cells. After TGFβ treatment, SMAD phosphorylation levels increased both in EV and in PMEPA1 overexpressing cells, but the fold increase was less pronounced in the case of SKOV3-PMEPA1 cells. On the contrary, we observed high levels of SMAD2/3 and P-SMAD2/3 proteins in SKOV3-shPMEPA1 compared to SCR (Fig. 6B ). Interestingly, reduced levels of SMAD2/3 in nuclear extracts were found in SKOV3-PMEPA1 cells, while the membrane bound SMAD2/3 increased ( fig. 6C ). Besides, we tested if PMEPA1 affected SMAD-dependent transcription of TGF-target genes using the CAGA-Luc reporter in SKOV3 cells. Transcriptional activity was not significantly affected by PMEPA1 overexpression although we observed a tendency towards lower luciferase activity, both in control and in TGF-treated cells (Fig. 6D ). In agreement to this, SERPINE1 (PAI-1) and EDN1 mRNA levels were lower in PMEPA1 overexpressing than in control cells ( fig. 6E ). On the other hand, PMEPA1 knockdown led to a significant reduction of the SMAD2/3-dependent reporter activity in untreated SKOV3 cells ( fig.   6D ) while no significant differences in SERPINE1 and EDN1 mRNA levels were found between the PMEPA1 knockdown and SCR cells. Interestingly, PMEPA1 mRNA expression significantly (p < 0.001) correlates with SERPINE1, EDN1 and TGFB1 (Pearson´s rho 0.47, 0.27 and 0.35, respectively, n = 427), as calculated with the UCSC Xena Cancer browser for TCGA Ovarian cancer. These results indicate that PMEPA1 is intrinsically related with the TGF pathway and should be considered as a necessary player for the pathway´s functions in cancer.
PMEPA1 promotes tumor growth in vivo
Finally, to confirm that PMEPA1 promotes ovarian tumor growth, we tested PMEPA1 overexpressing or knockdown cell lines growth in mice ( fig. 7 ). Several xenograft mouse models were used to address different aspects of ovarian cancer growth and metastasis. Nude mice were injected subcutaneously with 1x10 6 SKOV3-Luc EV or PMEPA1 overexpressing cells and tumor growth was monitored over time. Tumor volume growth was much higher in SKOV3-PMEPA1 compared to SKOV-EV derived tumor that became palpable around day 55 ( Fig. 7A ).
We were also able to follow and quantify tumor cell growth starting on the day of inoculation by bioluminescence. SKOV3-PMEPA1 xenografts showed a growth advantage when compared with SKOV3-EV xenografts from the beginning of the experiment (Fig. 7B ). Mice were sacrificed and tumors from subcutaneous xenografts were extracted and photographed and we corroborated the mentioned results (suppl. fig. 6 ). SKOV3-EV derived tumors were smaller; in some cases, we were not able to isolate a tumor mass, although we could detect bioluminescent signal. To confirm these results, we also performed a similar experiment, with subcutaneous injection of TOV112D and A2780 control and PMEPA1 overexpressing cells, in R2G2 mice. In the case of TOV112D cells, PMEPA overexpression increased tumor initiation rates to at least 50%, comparing to 25% in EV cells, PMEPA1 tumors grew faster, reaching maximum allowed size at least a month earlier than the EV ones (suppl. Fig 7) . On the other hand, only A2780-PMEPA1 cells, but not the EV, presented detectable growing tumors during a 15-week monitoring period (suppl. Fig 7) .
To further investigate the effects of PMEPA1 on tumor cell peritoneal dissemination, we injected intraperitoneally two SKOV3-PMEPA1 cell lines and SKOV3-EV cells. SKOV3-PMEPA1 xenografts had an important proliferative advantage, even more remarkable than in the subcutaneous experiments ( Fig. 7C ). To search for internal organ invasion, we extracted some organs (stomach, intestine, spleen, kidneys and pancreas) and peritoneal membrane. In mice that harbored SKOV3-PMEPA1, bio-luminescent signal could be detected in several internal organs, while in SKOV3-EV mice, all organs were negative (suppl. Fig. 8 ). Besides, peritoneal walls of SKOV3-PMEPA1 xenografts show localized luminescence signals corresponding to established metastases (suppl. Fig. 8 ). These results suggest that intraperitoneal dissemination and metastasis is facilitated by PMEPA1 overexpression.
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Finally, to recapitulate all the steps of ovarian cancer growth, dissemination and metastasis, cells were injected orthotopically into the ovary. SKOV3-PMEPA1 xenografts showed a strong growth advantage compared with SKOV3-EV, which could hardly form intra-ovary tumors (Fig. 7D ). More importantly, PMEPA1 knockdown SKOV3 grew even less, reaching even lower levels of BLI signal than SCR and much less than SKOV3-PMEPA1 xenografts (Fig. 3E) indicating that even the low PMEPA1 levels of control cells are important for tumor growth. Thus, the difference between overexpressing and silencing PMEPA1 in SKOV3 cells resulted in differences of about 20,000 fold in bioluminescence intensity.
Finally, to investigate the potential for these cells to develop metastasis, primary tumors were removed on day 35 (red arrow) and mice were monitored for bioluminescence, indicating metastatic tumor growth. A week after the operation, bioluminescence could be detected again, indicating cells had already metastasized (Fig. 7E ). Thus, PMEPA1 gives a clear advantage to ovarian tumor cells to adapt and grow in all the tested conditions. These in vivo results and the PMEPA1 expression in patient high-grade tumors strongly suggest that PMEPA1 could be an accurate biomarker of prognosis in ovarian cancer.
DISCUSSION
Elevated expression of Cyclooxygenase 2 (COX2) has been associated with development several cancers (36) and it is well established that COX2 inhibition can help prevent cancer (3) .
Besides, the importance of Calcineurin/NFAT signaling pathway in COX2 transcriptional induction and its involvement in colon tumor properties were already demonstrated by our group (1, 6) . PGF2 on the other hand, has only recently been associated with tumor progression in colorectal (6, 37) and endometrial cancer (38, 39) . Since it is naturally produced in the ovary and capable to produce strong effects on the epithelium (40) it would be logical to assume that it may have an important role also in ovarian cancer. Remarkably, although PTGFR levels are lower in ovarian tumors than in normal ovary, ovarian cancer patients with higher PTGFR mRNA levels exhibit lower survival probabilities than patients with lower PTGFR levels (suppl. Fig 9) .
These findings support studies on the implication of PTGFR in ovarian and other cancer types, since it appears to be an interesting pharmacological target against ovarian cancer dissemination and metastasis.
The TGF superfamily plays an important role in ovarian function and pathogenesis (41) while, remarkably, mutations in genes of this pathway are infrequent in ovarian cancer (27) . Importantly, we observed TGFB1 is up-regulated in ovarian cancer. We are the first to describe the induction of TGFB1 by PGF2 in cancer cells and our observation is supported by one earlier publication observing this induction in the bovine corpus luteum (42) . Not surprisingly, we found PTGFR and TGFB1 levels to be strongly correlated in ovarian tumors.
Furthermore, there is a strong correlation between the expression of TGFB1 and all the components of the COX2-PGF2-PTGFR-NFAT pathway tested. Moreover, we reported for the first time the association of Ca 2+ /Calcineurin/NFAT signaling with the transcriptional control of TGFB1. Furthermore, a cooperation of NFAT and EGR1 in the TGFB1 upregulation is highly plausible, since we have found several EGR1-binding sites in the TGFB1 promoter region, adjacent to NFAT-binding sites and we have already shown that EGR1 is also induced by PGF2 to regulate gene expression (6) .
We thus offer data that, for the first time, show the convergence between two pathways of great importance in cancer progression, TGF and COX2. COX2 products, such as PGF2, are able to induce TGFB1 transcription. This could further contribute to explain many of the effects of COX2 and PGs in the tumor setting, such as EMT (43), metastasis (44) and immune evasion (45) and could point out a potential interest in develop combined therapies including TGF and COX2 modulators in ovarian cancer.
As mentioned above, ovarian tumors rarely acquire mutations in the TGF pathway, although this cytokine is up-regulated in tumors over normal tissue. Thus, we sought to find a gene product that could allow tumor growth, involved in the evasion of the TGF tumor suppressor effects. One that fits this premise would be PMEPA1, already proposed to be a "molecular switch that converts TGF-β, normally a tumor suppressor, to a tumor promoter" (20) .
Indeed, we found that PMEPA1 is elevated in most ovarian tumors, its expression correlating with that of TGFB1. Remarkably, we found that PMEPA1 is induced also by PGF2/NFAT axis, as TGFB1, reaching a synergistic effect between the two pathways. Our data on the pro-tumoral effect of PMEPA1 in ovarian cancer are also supported by the fact that high PMEPA1 mRNA levels are associated with lower survival rate of patients. PMEPA1 overexpression increased tumor cell growth both in vitro and in vivo, as we demonstrate using different cell lines and in vivo tumor models, while it´s knockdown had the opposite effect. Thus, silencing PMEPA1 resulted in a much reduced tumor growth in vivo. More interestingly, our results also suggest that intraperitoneal dissemination and metastasis is facilitated by PMEPA1 overexpression. Given the fact that intracellular TGF signaling moderately decreased, we believe that PMEPA1 expressing cells are able to affect the tumor stroma without suffering the negative effects TGF could induce. PMEPA1 overexpression altered cell morphology, prompting a more epithelial phenotype, although TGF production by the cells increased. This altered morphology could be due to the up-regulation of E-cadherin we observed. Indeed, PMEPA1 was able to elevate functional E-cadherin levels and thus concentrate part of the -catenin in the intercellular junctions, while other epithelial markers failed to be induced. It has been already proposed that E-cadherin expression can have a positive effect on tumor aggressiveness and metastasis (46) , which would perfectly agree with our results. Moreover, we observed that PMEPA overexpressing cells, not only had elevated growth capacity on substrate, but also anchorage independent growth, in accordance with previous reports attributing this role to E-cadherin (47) . E-cadherin could be degraded upon different stimuli, as TGFβ (48), and thus lose association with β-catenin, that could translocate to the nucleus (49) . SKOV3-EV cells show β-catenin nuclear localization probably due to basal autocrine TGF- signaling (50) and absence of membrane Ecadherin. Even β-catenin remains in a cytoplasmic localization in PMEPA1 overexpressing cells, as we are the first to demonstrate. Indeed, after TGF-β treatment, more β-catenin translocated to the nucleus in SKOV3-EV cells but it remained cytoplasmic in SKOV3-PMEPA1 cells, indicating that PMEPA1 overexpression can block the β-catenin nuclear translocation. A plausible explanation to this phenomenon could be the fact that β-catenin can depend on SMAD3 to translocate to the nucleus (51, 52) . This is also supported by the fact that we found the same epithelial morphology and -catenin cytoplasmic localization when we treated cells with a latency associated peptide, inhibiting TGF or a TGFR inhibitor. Indeed, we also found that the overexpression of PMEPA1 reduced nuclear SMAD2/3, as already described in other cell systems (19, 20, 23) .
It is well established that E-cadherin expression and decreased cell mobility are common epithelial cell characteristics, while upregulation of N-cadherin, vimentin and zinc-finger domain proteins (SNAI1/SNAIL, SNAI2/SLUG), among others, are often linked to a mesenchymal-like phenotype (53) . A remarkable case is the ovarian surface epithelial (OSE) cells, in which overexpression of E-cadherin induces a number of epithelial characteristics and markers associated with malignant transformation and tumor progression (54) . Remarkably, both primary and metastatic ovarian carcinomas express E-cadherin, in contrast to normal ovarian surface epithelium, which rarely expresses E-cadherin (55, 56) . Further work should be done to elucidate the mechanisms through which PMEPA1 upregulates or avoids downregulation of Ecadherin and if these depend exclusively on TGFR signaling. Interestingly, PMEPA1 effects on growth can be observed only in ovarian carcinoma cell lines with mesenchymal or intermediate mesenchymal phenotype but not in OVCAR8 cells that are classified as epithelial. This supports idea that the effects of PMEPA1 in favoring an epithelial phenotype are linked to those on growth advantages.
A growing amount of evidence shows that PMEPA1 has a pro-tumoral role in different tissues (18, 57) while its pro-metastatic role is more controversial (58) . However, our findings show that PMEPA1 gives a clear pro-metastatic advantage to ovarian cancer cells. We believe that the PMEPA1 positive or negative effect on tumor growth could be related to a TGF-catenin or E-cadherin dependency of each tissue. Using a high grade ovarian tumor patient cohort, we found strong PMEPA1 expression in most tumors, perfectly correlating with Ecadherin and -catenin high expression. Bigger cohorts, including lower grade primary tumor biopsies should be used to confirm if PMEPA1 is linked to metastasis and its prognostic value.
All the above could indicate that PMEPA1 can tweak TGF signaling while making tumor cells produce more, upregulate E-cadherin protein levels and reduce -catenin nuclear localization, thus increasing cell plasticity and proliferation.
In conclusion, we show here a novel interaction between two signaling pathways important in cancer, COX2/prostaglandins/NFAT and TGF that leads to tumor progression and metastasis in ovarian cancer. Moreover, we demonstrate the importance of PGF2a and PMEPA1 20 in these processes. Further investigation on the role of PMEPA1 in ovarian cancer is necessary, since it might be an appropriate target for therapy and an accurate biomarker for prognosis and patient stratification, useful in clinical practice. 
MATERIALS AND METHODS
Ovarian samples
RNA extraction and RT-qPCR:
Total RNA was isolated using TRIzol reagent (Invitrogen) and following the manufacturer's protocol. qPCR analysis was performed using the GoTaq 2-
Step RT-PCR system (Promega) as described (6) Immunofluorescence was performed as described before (6) . Images were taken using a Zeiss Axioscop2 plus with a color CCD camera or the Zeiss LSM710 confocal microscope.
Western blotting was performed as described before (6) . 
